Kane Biotech Inc V.KNE

New Corporate Presentation

[francoisl13]

I didn't look at it (yet) but here's a link to the latest company presentation;
Kane - September 2024 Presentation
GLTA!

[francoisl13]

This new presentation is refreshing to see, here's why; 1. They are focusing on Revyve; 2. They are providing 'sales guidance or forecast' for Revyve (this is a first in their case); 3. They show a list of announcements (some are potentials only) and goals for Q3, Q4 and H1 2025 which makes it clearer for investors with regards to where the company is heading and how; 4. They are also

[francoisl13]

Only 'negative' is that they are looking at some 'financing' in Q3/24 which means very soon... This was expected considering the expenses level vs actual revenue -- see previous posts on this board from August/Sept.

[KevinOleary]

Read the posts on ceo.ca because there are a few important items tht you didn't list.

[francoisl13]

The CEO post is okay. The only point mentioned in there that's worth discussing is the upcoming financing. 1. Will they issuing shares? How many (dilution)? At what price? Are they going to attract new investors (I hope), new partners (pretty good option), investment funds (could be good - depends on the deal details); 2. Will they go the debt route using the good relationship they have with

[francoisl13]

Sorry , should have wrote ''the CEO.CA' post or forum in my previous pot...

[KevinOleary]

No one finances someone else for free, so there will be dilution. The financing is for an acquisition. There is no mention of any financing required for other operations, so we don't know what their internal forecast is yet. The $3M per product per year is probably all the exchange allows kne to say publicly at this stage, but that doesn't prove kne thinks that's the maximum they will

[francoisl13]

All good points. Thanks (again) for sharing, always appreciated. Having respectful and polite discussion on a forum like this one is great. Your point about the fact that there was no mention of a financing required to support operation is well taken but still, looking at their expenses rate and the sales forecast/expectations makes me think that they might get a little short on money and pretty

[KevinOleary]

Even if you get no dilution bank debt, the bank is only going to put up part of the total money needed, so the company would need to raise money. We have to wait patiently for the news this month.

[francoisl13]

Absolutely agree but the news is likely going to be next month (ie.: next QTR)....

[KevinOleary]

The presentation says Sept.

[KevinOleary]

You're right, they updated the presentation today, to Q4.

[MirrorWorldMan]

Revenue guidance is welcomed, professional and appropriate.  Its a solid objective to measure performance of the management team and if anything, seems low to me anyway. I hope Marc is under promising...   Financings I would bet would be similar to previous loans, Marc tries to avoid over dilution but I guess there would be warrants involved to sweeten the deal to the lender.  Could

[KevinOleary]

The exchange limits how much forward guidance you can provide without revenues. You think exactly $3M per product, per year is a scientific calculation? Wait for a few quarters to see how Revyve and the mystery acquisition does instead of impatiently demanding info that can't be provided, then pretending $3M is useful.